Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Sunshine Biopharma Inc. (SBFM)

Add SBFM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BooDog, Gordon Buffett
Search This Board:
Last Post: 12/19/2014 12:38:53 PM - Followers: 173 - Board type: Free - Posts Today: 0




"The Future Of Medicine"


Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 


Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 

Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697


Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.

Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options





Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.

Check out SBFM's drug Adva-27a (27a) vs the leading chem drug Etoposide (2) - results are better in every category except two. And in the multi drug resistance breast cancer category (MCF7R) it's over 3x more effective. 

Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).

The U.S. Food and Drug Administration's (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma's Lead Compound could significantly exceed the typical Revenues generated from anti-cancer drugs, which in general reach $1 Billion in annual sales within two or three years of FDA Approval.

Sunshine Biopharma Drug Pipeline

Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug

November 19, 2014
Montreal, Quebec, Canada -- (Marketwire) -- Sunshine Biopharma Inc. (OTCQB: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a.  Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine’s Adva-27a.  Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization.  Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
“We are delighted to have a global leader like Lonza as our manufacturing partner,” said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma.  “We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts.”
“We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound”, said James Leresche, Ph.D., Head of Lonza’s Chemical Development Services. “This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma & Biotech and Specialty Ingredients. Further information can be found at
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).  Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.  The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz:
Joshua Ciarrocca:
Tel.: (416) 644-2020 or (514) 939-3989
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464,
Lonza Media Contacts:
Colleen Floreck, +1 201 316 9290,
Constance Ward, +41 61 316 8840,
Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.

Nansha China

Visp Switzerland

SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals

We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.  Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”).  As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management.  Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”.  On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.

Intellectual Property

We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697).  These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation.  On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.
Advanomics Corporation, the Parent Company of Sunshine Biopharma

Head Office:

Advanomics Corporation

2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8

Tel: 514-764-9698
Fax: 514-764-9699

Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz:
Joshua Ciarrocca:
Tel.: (416) 644-2020 or (514) 939-3989
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464,

Product Pipeline

Our product pipeline is comprised of the following anti-tumor compounds:


Entering Phase I later this year (Lead Compound)



RNAi Anti-Cancer drug candidate
Soon to enter animal studies phase



Currently in preclinical phase


SBFM Share Structure

From and SEC filings
The number of shares of the registrant’s only class of common stock issued and outstanding as of November 10, 2014, was 68,911,041 shares.

Authorized Shares 200,000,000 a/o Dec 31, 2011

31.5 million held by Steve Slilaty, CEO

SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

Sunshine Biopharma Inc.
2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Tel: 514-764-9698
Fax: 514-764-9699






  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
SBFM News: Current Report Filing (8-k) 11/19/2014 04:01:04 PM
SBFM News: Quarterly Report (10-q) 11/12/2014 07:01:12 AM
SBFM News: Quarterly Report (10-q) 08/12/2014 05:26:36 PM
SBFM News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/28/2014 04:05:06 PM
SBFM News: Notice of Effectiveness (effect) 07/24/2014 06:01:50 AM
#18512  Sticky Note November 19, 2014 Delivery of an initial batch BooDog 11/20/14 06:08:06 AM
#11692  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 10/09/13 10:52:01 AM
#18695   We'll see. as the micros loom closer and BooDog 12/19/14 12:38:53 PM
#18694   SBFM MAINIPULATED COM'ON !!! After reading the November stockmeiyc 12/19/14 10:39:08 AM
#18693   An investigation from the governing bodies should be launched! Gordon Buffett 12/19/14 10:15:25 AM
#18692   When something is worthless, the end result is Kalinn 12/17/14 04:16:39 PM
#18691   been watching this into the close... company has Kalinn 12/17/14 04:14:12 PM
#18690   What the hell is going on... Bottomless! reginaliberta 12/17/14 03:59:10 PM
#18689   Well I'm pretty much speechless. I can't recall reportmyabuse 12/17/14 03:56:09 PM
#18688   Pretty obvious that they don't care about taking BooDog 12/16/14 04:11:34 PM
#18687   5 million shares sold off this month alone... Kalinn 12/16/14 04:06:47 PM
#18686   Thanks for your insight. The dumping of this reportmyabuse 12/16/14 03:58:21 PM
#18685   ... and may be extended or terminated earlier Kalinn 12/16/14 03:54:46 PM
#18684   This is definitely a good time to pick reportmyabuse 12/16/14 03:54:18 PM
#18683   Aye! So the purchase order will just never reportmyabuse 12/16/14 03:51:31 PM
#18682   Item 1.01 Entry into a Material Definitive Agreement Kalinn 12/16/14 03:43:47 PM
#18681   I just read the news articles. Are you reportmyabuse 12/16/14 03:39:37 PM
#18680   My plan is to slide my own order BooDog 12/16/14 03:29:15 PM
#18679   did you even read the Lonza deal, it's Kalinn 12/16/14 03:26:18 PM
#18678   Sheesh. Ask now $0.025. 50,000 shares. I can reportmyabuse 12/16/14 03:16:18 PM
#18677   only a matter of time Gordon Buffett 12/15/14 11:41:01 AM
#18675   Guessing they had to pay the rent and BooDog 12/12/14 05:24:59 AM
#18674   Yea, looks like it. One fugly chart. Commando911 12/11/14 10:46:58 PM
#18673   This turd is going to tripps Cash Monster 12/11/14 08:53:56 PM
#18672   Big volume. Turd pps Cash Monster 12/11/14 08:49:54 PM
#18671   If more morons sell shares to declare december reginaliberta 12/11/14 08:37:01 PM
#18670   Sbfm needs to work on its credibility, and reginaliberta 12/11/14 08:32:58 PM
#18669   After today, 18 weeks seems far away. Management needs reginaliberta 12/11/14 08:16:31 PM
#18668   Looks like that is what it is turning reportmyabuse 12/11/14 08:02:53 PM
#18667   This is a piece of crap junk. Jimmythegreek 12/11/14 06:03:15 PM
#18666   4,500,000 shares dumped so far in November, these Kalinn 12/11/14 04:25:37 PM
#18665   MEAT ? ... its called SBFM is DEAD navycmdr 12/11/14 04:11:37 PM
#18664   I think we've all had the suspicion that reportmyabuse 12/11/14 03:23:23 PM
#18663   18 weeks to go, isn't it? isn't that Kalinn 12/11/14 03:17:28 PM
#18662   at least if can't go negative... lol Kalinn 12/11/14 03:09:26 PM
#18661   four years of endless PRs with no matching Kalinn 12/11/14 03:04:03 PM
#18660   Forget who is buying...the question is who is MKAT 12/11/14 03:02:47 PM
#18659   Wow, there is just no floor on this reportmyabuse 12/11/14 01:42:20 PM
#18658   Its been over 3 years people have been Cash Monster 12/11/14 08:07:53 AM
#18657   Gordon...whats your target for SBFM for next several optionking 12/10/14 10:13:01 PM
#18656   Company- if you want to call it that...3 Kalinn 12/10/14 08:55:52 PM
#18655   They finally materialized an event,woo-hoo record low Cash Monster 12/10/14 07:02:30 PM
#18654   I guess I jumped the gun by having reportmyabuse 12/10/14 06:06:00 PM
#18653   Even Charlie Brown got wise of Lucy pulling Kalinn 12/10/14 06:18:52 AM
#18652   WHAT HAPPENS WITH SOLID NEWS WITH MEAT ON IT? Angel21stCentury 12/08/14 06:32:33 PM
#18651   LOOK STRAIT UP IN THE SKYDESTINATION MOON$$$$$ Angel21stCentury 12/08/14 06:06:30 PM
#18650   no my boy it does not sound shiny... thanks larson1 12/08/14 04:48:40 PM
#18645   Sbfm is a strong buy. reginaliberta 12/07/14 11:07:32 PM
#18644   Sbfm shall march back to teens IMHO Once reginaliberta 12/07/14 11:06:30 PM
#18643   LONZA WILL SHOCK THE WORLD ADVA-27A MIRACLE CANCER DRUG Angel21stCentury 12/07/14 11:05:21 PM
#18640   Good things coming here.... Hang on reginaliberta 12/07/14 10:55:31 PM
#18639   WE NEED SERIOUS NEWS AND AWAY WE GO$$$$$$$$$$$$ Angel21stCentury 12/07/14 10:54:06 PM